Investors / filer profile

Nagendran Sukumar

President and Head of R&D

active in 1 company

Pro
Bought: Pro
Sold: 15
Filings: 1
Companies: 2026-07-10
Last filed

EDGAR · CIK 0001665124 ↗

Track record

How each disclosed position did against the S&P ~6 months later

No positions we can measure against the market yet — outcomes appear once a disclosed buy is ~6 months old.

Disclosed positions

Estimated from their latest filings — positions may have changed since

Estimated positions from their latest filingsPro →

Activity

Open-market buy & sell volume

BuySell

Total +$0.0000 bought · −$5.24M sold

All filings on record

Every Form 4 transaction we track for this filer


TSHATaysha Gene Therapies, Inc.	Sell $1.25M · 200,000 sh	2026-07-10	—
TSHATaysha Gene Therapies, Inc.	Sell $124.1K · 26,918 sh	2026-01-26	—
TSHATaysha Gene Therapies, Inc.	Sell $423.4K · 89,132 sh	2026-01-23	—
TSHATaysha Gene Therapies, Inc.	Grant — · 427,000 sh	2026-01-12	—
TSHATaysha Gene Therapies, Inc.	Sell $942.0K · 200,000 sh	2026-01-12	—
TSHATaysha Gene Therapies, Inc.	Exercise $151.6K · 88,676 sh	2026-01-12	—
TSHATaysha Gene Therapies, Inc.	Exercise $77.8K · 111,324 sh	2026-01-12	—
TSHATaysha Gene Therapies, Inc.	Sell $1.17M · 260,047 sh	2025-12-01	—
TSHATaysha Gene Therapies, Inc.	Exercise $444.7K · 260,047 sh	2025-12-01	—
TSHATaysha Gene Therapies, Inc.	Sell $523.1K · 110,125 sh	2025-11-28	—

TSHASell

2026-07-10 · Taysha Gene Therapies, Inc.

$1.25M

—

TSHASell

2026-01-26 · Taysha Gene Therapies, Inc.

$124.1K

—

TSHASell

2026-01-23 · Taysha Gene Therapies, Inc.

$423.4K

—

TSHAGrant

2026-01-12 · Taysha Gene Therapies, Inc.

427,000

—

TSHASell

2026-01-12 · Taysha Gene Therapies, Inc.

$942.0K

—

TSHAExercise

2026-01-12 · Taysha Gene Therapies, Inc.

$151.6K

—

TSHAExercise

2026-01-12 · Taysha Gene Therapies, Inc.

$77.8K

—

TSHASell

2025-12-01 · Taysha Gene Therapies, Inc.

$1.17M

—

TSHAExercise

2025-12-01 · Taysha Gene Therapies, Inc.

$444.7K

—

TSHASell

2025-11-28 · Taysha Gene Therapies, Inc.

$523.1K

—

Newest 10 of 15 filingsEvery Form 4 on record, with outcomesPro →

Outcomes measure each position — the first buy in a stock and every buy within 182 days — against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.